Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
EMBO Mol Med ; 13(11): e14434, 2021 11 08.
Artículo en Inglés | MEDLINE | ID: mdl-34606154

RESUMEN

Pompe disease is a metabolic myopathy due to acid alpha-glucosidase deficiency. In addition to glycogen storage, secondary dysregulation of cellular functions, such as autophagy and oxidative stress, contributes to the disease pathophysiology. We have tested whether oxidative stress impacts on enzyme replacement therapy with recombinant human alpha-glucosidase (rhGAA), currently the standard of care for Pompe disease patients, and whether correction of oxidative stress may be beneficial for rhGAA therapy. We found elevated oxidative stress levels in tissues from the Pompe disease murine model and in patients' cells. In cells, stress levels inversely correlated with the ability of rhGAA to correct the enzymatic deficiency. Antioxidants (N-acetylcysteine, idebenone, resveratrol, edaravone) improved alpha-glucosidase activity in rhGAA-treated cells, enhanced enzyme processing, and improved mannose-6-phosphate receptor localization. When co-administered with rhGAA, antioxidants improved alpha-glucosidase activity in tissues from the Pompe disease mouse model. These results indicate that oxidative stress impacts on the efficacy of enzyme replacement therapy in Pompe disease and that manipulation of secondary abnormalities may represent a strategy to improve the efficacy of therapies for this disorder.


Asunto(s)
Enfermedad del Almacenamiento de Glucógeno Tipo II , Animales , Terapia de Reemplazo Enzimático , Glucógeno/metabolismo , Enfermedad del Almacenamiento de Glucógeno Tipo II/tratamiento farmacológico , Humanos , Ratones , Estrés Oxidativo , alfa-Glucosidasas/metabolismo , alfa-Glucosidasas/uso terapéutico
2.
J Enzyme Inhib Med Chem ; 36(1): 2068-2079, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34565280

RESUMEN

Pompe disease is an inherited metabolic disorder due to the deficiency of the lysosomal acid α-glucosidase (GAA). The only approved treatment is enzyme replacement therapy with the recombinant enzyme (rhGAA). Further approaches like pharmacological chaperone therapy, based on the stabilising effect induced by small molecules on the target enzyme, could be a promising strategy. However, most known chaperones could be limited by their potential inhibitory effects on patient's enzymes. Here we report on the discovery of novel chaperones for rhGAA, L- and D-carnitine, and the related compound acetyl-D-carnitine. These drugs stabilise the enzyme at pH and temperature without inhibiting the activity and acted synergistically with active-site directed pharmacological chaperones. Remarkably, they enhanced by 4-fold the acid α-glucosidase activity in fibroblasts from three Pompe patients with added rhGAA. This synergistic effect of L-carnitine and rhGAA has the potential to be translated into improved therapeutic efficacy of ERT in Pompe disease.


Asunto(s)
Carnitina/farmacología , Inhibidores de Glicósido Hidrolasas/farmacología , Lisosomas/efectos de los fármacos , Chaperonas Moleculares/farmacología , alfa-Glucosidasas/metabolismo , Regulación Alostérica/efectos de los fármacos , Carnitina/química , Relación Dosis-Respuesta a Droga , Inhibidores de Glicósido Hidrolasas/química , Humanos , Lisosomas/enzimología , Chaperonas Moleculares/química , Estructura Molecular , Relación Estructura-Actividad
3.
Mol Ther Methods Clin Dev ; 15: 333-342, 2019 Dec 13.
Artículo en Inglés | MEDLINE | ID: mdl-31788497

RESUMEN

Mucopolysaccharidosis type IIIA (MPS-IIIA) is a lysosomal storage disorder (LSD) caused by inherited defect of sulfamidase, a lysosomal sulfatase. MPS-IIIA is one of the most common and severe forms of LSDs with CNS involvement. Presently there is no cure. Here we have developed a new gene delivery approach for the treatment of MPS-IIIA based on the use of a modified version of sulfamidase expression cassette. This cassette encodes both a chimeric sulfamidase containing an alternative signal peptide (sp) to improve enzyme secretion and sulfatase-modifying factor 1 (SUMF1) to increase sulfamidase post-translational activation rate. We demonstrate that improved secretion and increased activation of sulfamidase act synergistically to enhance enzyme biodistribution in wild-type (WT) pigs upon intrathecal adeno-associated virus serotype 9 (AAV9)-mediated gene delivery. Translating such gene delivery strategy to a mouse model of MPS-IIIA results in a rescue of brain pathology, including memory deficit, as well as improvement in somatic tissues. These data may pave the way for developing effective gene delivery replacement protocols for the treatment of MPS-IIIA patients.

4.
Development ; 143(9): 1452-63, 2016 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-26989172

RESUMEN

Mouse fetal intestinal progenitors lining the epithelium prior to villogenesis grow as spheroids when cultured ex vivo and express the transmembrane glycoprotein Trop2 as a marker. Here, we report the characterization of Trop2-expressing cells from fetal pre-glandular stomach, growing as immortal undifferentiated spheroids, and their relationship with gastric development and regeneration. Trop2(+) cells generating gastric spheroids differed from adult glandular Lgr5(+) stem cells, but appeared highly related to fetal intestinal spheroids. Although they shared a common spheroid signature, intestinal and gastric fetal spheroid-generating cells expressed organ-specific transcription factors and were committed to intestinal and glandular gastric differentiation, respectively. Trop2 expression was transient during glandular stomach development, being lost at the onset of gland formation, whereas it persisted in the squamous forestomach. Undetectable under homeostasis, Trop2 was strongly re-expressed in glands after acute Lgr5(+) stem cell ablation or following indomethacin-induced injury. These highly proliferative reactive adult Trop2(+) cells exhibited a transcriptome displaying similarity with that of gastric embryonic Trop2(+) cells, suggesting that epithelium regeneration in adult stomach glands involves the partial re-expression of a fetal genetic program.


Asunto(s)
Antígenos de Neoplasias/metabolismo , Moléculas de Adhesión Celular/metabolismo , Epitelio/crecimiento & desarrollo , Epitelio/lesiones , Mucosa Gástrica/embriología , Regeneración/fisiología , Esferoides Celulares/fisiología , Células Madre Adultas/citología , Animales , Biomarcadores/metabolismo , Células Cultivadas , Desarrollo Embrionario/fisiología , Indometacina/toxicidad , Ratones , Ratones Transgénicos , Técnicas de Cultivo de Órganos
5.
Mol Ther ; 24(2): 276-286, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26639405

RESUMEN

Cerebrospinal fluid administration of recombinant adeno-associated viral (rAAV) vectors has been demonstrated to be effective in delivering therapeutic genes to the central nervous system (CNS) in different disease animal models. However, a quantitative and qualitative analysis of transduction patterns of the most promising rAAV serotypes for brain targeting in large animal models is missing. Here, we characterize distribution, transduction efficiency, and cellular targeting of rAAV serotypes 1, 2, 5, 7, 9, rh.10, rh.39, and rh.43 delivered into the cisterna magna of wild-type pigs. rAAV9 showed the highest transduction efficiency and the widest distribution capability among the vectors tested. Moreover, rAAV9 robustly transduced both glia and neurons, including the motor neurons of the spinal cord. Relevant cell transduction specificity of the glia was observed after rAAV1 and rAAV7 delivery. rAAV7 also displayed a specific tropism to Purkinje cells. Evaluation of biochemical and hematological markers suggested that all rAAV serotypes tested were well tolerated. This study provides a comprehensive CNS transduction map in a useful preclinical large animal model enabling the selection of potentially clinically transferable rAAV serotypes based on disease specificity. Therefore, our data are instrumental for the clinical evaluation of these rAAV vectors in human neurodegenerative diseases.


Asunto(s)
Sistema Nervioso Central/metabolismo , Dependovirus/genética , Vectores Genéticos/administración & dosificación , Vectores Genéticos/líquido cefalorraquídeo , Proteínas Fluorescentes Verdes/metabolismo , Animales , Dependovirus/inmunología , Técnicas de Transferencia de Gen , Proteínas Fluorescentes Verdes/genética , Humanos , Especificidad de Órganos , Serogrupo , Porcinos , Transducción Genética , Transgenes
6.
Cell Rep ; 5(2): 421-32, 2013 Oct 31.
Artículo en Inglés | MEDLINE | ID: mdl-24139799

RESUMEN

Immortal spheroids were generated from fetal mouse intestine using the culture system initially developed to culture organoids from adult intestinal epithelium. Spheroid proportion progressively decreases from fetal to postnatal period, with a corresponding increase in production of organoids. Like organoids, spheroids show Wnt-dependent indefinite self-renewing properties but display a poorly differentiated phenotype reminiscent of incompletely caudalized progenitors. The spheroid transcriptome is strikingly different from that of adult intestinal stem cells, with minimal overlap of Wnt target gene expression. The receptor LGR4, but not LGR5, is essential for their growth. Trop2/Tacstd2 and Cnx43/Gja1, two markers highly enriched in spheroids, are expressed throughout the embryonic-day-14 intestinal epithelium. Comparison of in utero and neonatal lineage tracing using Cnx43-CreER and Lgr5-CreERT2 mice identified spheroid-generating cells as developmental progenitors involved in generation of the prenatal intestinal epithelium. Ex vivo, spheroid cells have the potential to differentiate into organoids, qualifying as a fetal type of intestinal stem cell.


Asunto(s)
Mucosa Intestinal/citología , Receptores Acoplados a Proteínas G/metabolismo , Células Madre/metabolismo , Animales , Antígenos de Neoplasias/metabolismo , Moléculas de Adhesión Celular/metabolismo , Diferenciación Celular , Linaje de la Célula , Conexina 43/metabolismo , Embrión de Mamíferos/citología , Embrión de Mamíferos/metabolismo , Ratones , Organoides/citología , Esferoides Celulares , Células Madre/citología , Transcriptoma
7.
EMBO Rep ; 12(6): 558-64, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21508962

RESUMEN

Gene inactivation of the orphan G protein-coupled receptor LGR4, a paralogue of the epithelial-stem-cell marker LGR5, results in a 50% decrease in epithelial cell proliferation and an 80% reduction in terminal differentiation of Paneth cells in postnatal mouse intestinal crypts. When cultured ex vivo, LGR4-deficient crypts or progenitors, but not LGR5-deficient progenitors, die rapidly with marked downregulation of stem-cell markers and Wnt target genes, including Lgr5. Partial rescue of this phenotype is achieved by addition of LiCl to the culture medium, but not Wnt agonists. Our results identify LGR4 as a permissive factor in the Wnt pathway in the intestine and, as such, as a potential target for intestinal cancer therapy.


Asunto(s)
Diferenciación Celular , Mucosa Intestinal/metabolismo , Células de Paneth/citología , Receptores Acoplados a Proteínas G/metabolismo , Células Madre/metabolismo , Animales , Perfilación de la Expresión Génica , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Técnicas de Inactivación de Genes , Intestinos/citología , Cloruro de Litio/farmacología , Ratones , Ratones Noqueados , Organoides/crecimiento & desarrollo , Organoides/metabolismo , Fenotipo , Receptores Acoplados a Proteínas G/genética , Células Madre/citología
8.
Dev Biol ; 331(1): 58-67, 2009 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-19394326

RESUMEN

The orphan Leucine-rich repeat G protein-coupled receptor 5 (LGR5/GPR49), a target of Wnt signaling, is a marker of adult intestinal stem cells (SC). However, neither its function in the adults, nor during development of the intestine have been addressed yet. In this report, we investigated the role of LGR5 during ileal development by using LGR5 null/LacZ-NeoR knock-in mice. X-gal staining experiments showed that, after villus morphogenesis, Lgr5 expression becomes restricted to dividing cells clustered in the intervillus region and is more pronounced in the distal small intestine. At day E18.5, LGR5 deficiency leads to premature Paneth cell differentiation in the small intestine without detectable effects on differentiation of other cell lineages, nor on epithelial cell proliferation or migration. Quantitative RT-PCR experiments showed that expression from the LGR5 promoter was upregulated in LGR5-null mice, pointing to the existence of an autoregulatory negative feedback loop in intact animals. This deregulation was associated with overexpression of Wnt target genes in the intervillus epithelium. Transcriptional profiling of mutant mice ileums revealed that LGR5 function is associated with expression of SC and SC niche markers. Together, our data identify LGR5 as a negative regulator of the Wnt pathway in the developing intestine.


Asunto(s)
Regulación del Desarrollo de la Expresión Génica , Intestino Delgado/embriología , Células de Paneth/citología , Receptores Acoplados a Proteínas G/genética , Proteínas Wnt/fisiología , Animales , Secuencia de Bases , Bromodesoxiuridina , Diferenciación Celular , División Celular , Movimiento Celular , Cartilla de ADN , Desarrollo Embrionario/genética , Femenino , Expresión Génica , Íleon/embriología , Hibridación in Situ , Intestino Delgado/citología , Ratones , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Análisis de Secuencia por Matrices de Oligonucleótidos , Embarazo , Receptores Acoplados a Proteínas G/deficiencia , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transcripción Genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...